Adds trial details in paragraph 2, disease background in paragraph 3 and share movement in paragraph 4
Dec 17 (Reuters) - Sanofi SASY.PA and Teva Pharmaceuticals TEVA.TA said on Tuesday that their drug, duvakitug, met the main goals in a mid-stage trial when tested in patients with inflammatory bowel disease $(IBD)$.
The drug met the main goals of disease remission and effectiveness for the treatment of ulcerative colitis and Crohn's disease, respectively.
These are the two most common forms of IBD, which affects between 2.4 million and 3.1 million people in the U.S.
U.S.-listed shares of Teva rose nearly 14%, while U.S.-listed shares of Sanofi climbed 4% premarket.
(Reporting by Christy Santhosh in Bengaluru; Editing by Shailesh Kuber)
((Christy.Santhosh@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。